CLINICAL TRIALS PROFILE FOR MICAFUNGIN
✉ Email this page to a colleague
505(b)(2) Clinical Trials for MICAFUNGIN
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Dosage | NCT02372357 ↗ | A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area | Completed | Institutul Clinic Fundeni | Phase 4 | 2012-02-01 | A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy. |
| New Dosage | NCT02372357 ↗ | A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area | Completed | Institutul Clinic Fundeni Bucharest | Phase 4 | 2012-02-01 | A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy. |
| New Dosage | NCT02372357 ↗ | A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area | Completed | Universitaire Ziekenhuizen Leuven | Phase 4 | 2012-02-01 | A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for MICAFUNGIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00047827 ↗ | Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis | Terminated | Astellas Pharma Inc | Phase 2 | 2002-12-01 | The purpose of this study is to evaluate the safety and effectiveness of micafungin in combination with AmBisome as first-line therapy in the treatment of invasive aspergillosis. |
| NCT00048750 ↗ | Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU | Terminated | Astellas Pharma Inc | Phase 3 | 2003-01-01 | The purpose of this study is to determine the efficacy and safety of intravenous micafungin versus placebo as prophylactic therapy for invasive fungal infections in patients in the intensive care unit considered to be at high risk. |
| NCT00105144 ↗ | Study of Micafungin in Patients With Invasive Candidiasis or Candidemia | Completed | Astellas Pharma Inc | Phase 3 | 2004-09-01 | The purpose of the study is to determine the safety and effectiveness of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia. |
| NCT00106288 ↗ | Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia | Completed | Astellas Pharma Inc | Phase 3 | 2003-01-01 | The purpose of this study is to determine the efficacy and safety of micafungin (FK463) versus liposomal amphotericin B (AmBisome) in treating neutropenic and non-neutropenic patients with confirmed invasive candidiasis or candidemia. Enrollment will include adult and pediatric patients. |
| NCT00189709 ↗ | Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia | Completed | Astellas Pharma Taiwan, Inc. | Phase 3 | 2004-08-01 | To determine the efficacy and safety of micafungin (FK463) versus fluconazole (Diflucan) in treating patients with invasive candidiasis or candidaemia |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MICAFUNGIN
Condition Name
Clinical Trial Locations for MICAFUNGIN
Trials by Country
Clinical Trial Progress for MICAFUNGIN
Clinical Trial Phase
Clinical Trial Sponsors for MICAFUNGIN
Sponsor Name
